Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET study of alternating lutetium-177 PSMA radioligand therapy and radium-223 in oligometastatic hormone-sensitive prostate cancer
NL-OMON56209Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of radium-223 dichloride and lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) and Metastatic Prostate Cancer (mPC), sponsored by Amsterdam University Medical Center. Primary endpoint: Feasibility and safety of drug application. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
radium-223 dichloridelutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NL-OMON56209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56209.